Erratum: Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

摘要

This erratum is being published to correct the company errors on the article “Delamanid, Bedaquiline, and Line zolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resis tant and Extensively Drug-resistant Tuberculosis in Korea” Ann Lab Med 2018;38(6):563-8 https://doi.org/10.3343/alm.2018.38.6.563 Before correction: Page 564: 2. Anti-TB drugs Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan), bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium), and linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea). After correction: Page 564: 2. Anti-TB drugs Delamanid powder was obtained from Otsuka Pharmaceutical (Tokyo, Japan) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Bedaquiline powder was obtained from Janssen Pharmaceutica (Beerse, Belgium) and Advanced ChemBlocks Inc (Burlingame, CA, USA). Linezolid was supplied by Yungjin Pharmaceutical (Seoul, Korea).